PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS

• N. Rajakumaraswamy,
• M. Gandhi,
• A. H. Wei,
• D. A. Sallman,
• N. G. Daver,
• S. Mo,
• S. Iqbal,
• M. Chen,
• Y. Wang,
• P. Vyas

Affiliations

N. Rajakumaraswamy

1 Gilead Sciences, Inc., Foster City

M. Gandhi

2 Virginia Cancer Specialists, Fairfax, United States of America

A. H. Wei

3 Department of Clinical Haematology, The Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

D. A. Sallman

4 Moffitt Cancer Center, Tampa

N. G. Daver

5 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston

S. Mo

1 Gilead Sciences, Inc., Foster City

S. Iqbal

1 Gilead Sciences, Inc., Foster City

M. Chen

1 Gilead Sciences, Inc., Foster City

Y. Wang

6 Ontada, The Woodlands, United States of America

P. Vyas

7 Department of Medicine, University of Oxford Radcliffe, Oxford, United Kingdom